Q3 2025 Earnings Call November 14, 2025 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical facts included in this presentation, including, without limitation, with respect to T1 Energy Inc.'s ("T1") strategy of developing a U.S. silicon-based solar supply chain, supporting AI power demand, reshoring American PV solar manufacturing and T1's a ...

Fiscal 2025 4Q and Full Year Financial Results N O V E M B E R 2 0 2 5 Agenda Welcome Angela Bitting SVP, Corporate Affairs Quarterly Highlights Emily Leproust Chief Executive Officer Business Highlights Patrick Finn President and Chief Operating Officer Financial and Operational Performance Adam Laponis Chief Financial Officer Milestones Emily Leproust Chief Executive Officer Q&A Session 2 | TWIST BIOSCIENCE | PROPRIETARY Legal Disclaimers This presentation contains forward-looking statements. All statemen ...

Forward-Looking Information / Statements Certain statements contained in this presentation are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "plans," "expects," "believes," "anticipates," and similar words are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning our expected revenue growth and improved profitability, and ou ...

Teleflex Incorporated Vascular Intervention Investor Call November 14, 2025 Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) An audio replay of the call will be available beginning at 11:00 am Eastern Time on November 14, 2025 either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S.) or 1 609 800 9909 (all other locations). The confirmation code is 61210. Today's Speake ...

Financial Performance - Total revenue for Q3 2025 was $2.2 million, a 13% sequential increase[14, 15] - Bitcoin mining revenue contributed $2.0 million to the total revenue, up 11.3% sequentially[15] - Mining margin improved to 49% in Q3 2025, up from 41% in Q2 2025[11, 15] - The company experienced a net loss of $3.7 million and a Core EBITDA loss of $1.4 million in Q3 2025[15] Operational Highlights - Bitcoin holdings as of October 31, 2025, were 294.9 BTC, valued at $32.2 million[7, 17, 18, 20, 24, 25] - The company's energized hashrate reached 0.70 EH/s exiting Q3 2025[11] - The 11 MW Mississippi site was fully integrated, with 7.5 MW actively mining, resulting in a 28% increase in BTC production for October[11] Strategic Initiatives - The company completed an $8 million private repurchase of 3.3 million shares and 7.2 million warrants[7, 15] - A $1.5 million public share buyback program was authorized[7, 15] - The company secured S21 immersion miners for Oklahoma, with energization expected in December 2025[7, 11]

Financial Performance - Net revenues reached RMB 1,129 million, a 49% year-over-year increase[11] - Gross profit was RMB 353 million, with a year-over-year growth of 71%[8,9] - Non-GAAP operating profit amounted to RMB 188 million, showing a 124% year-over-year increase[8,10] - Gross margin steadily improved, reaching 31.2% in 2025 Q3[38,120] Capital Resources - Total capital resources stood at RMB 15.4 billion[11] - Cash and cash equivalents amounted to RMB 3.5 billion[11] - Operating cash flow generated was USD 501 million[14] Shareholder Value - Total capital returned to shareholders since IPO reached RMB 0.4 billion, with 66% in the form of share repurchases[17] Business Growth - International business experienced significant growth, outperforming the industry average, with a 72% year-over-year increase in revenues from international business[7,34,35] - The company achieved a moderate recovery in its Mainland China business[7]

Financial Performance - Azul achieved record-high revenue of R$5.7 billion in 3Q25, an 11.8% increase compared to 3Q24[11] - The company's EBITDA reached R$2.0 billion in 3Q25, with a 34.6% margin, representing a 20.2% increase compared to 3Q24[11] - EBIT was R$1.3 billion with a 22.1% margin, a 23.7% increase compared to 3Q24[11] - RASK (Revenue per Available Seat Kilometer) increased by 4.4% to R$44.76 cents in 3Q25 compared to 3Q24[11] Operational Efficiency - ASK (Available Seat Kilometers) grew by 7.1%, reaching 12.8 billion in 3Q25[16] - Productivity increased by 8.6%, reaching 861 million ASK per FTE in 3Q25[20] - Load factor improved by 2.0 percentage points to 84.6% in 3Q25[20] - Adjusted CASK (Cost per Available Seat Kilometer) decreased by 2.0% from 2Q25 to 3Q25, reaching R$34.85 cents[24, 25] Business Growth - "Beyond the Metal" business units experienced continued growth, contributing significantly to net revenue[12, 13]

NOVEMBER 2025 ACS Investor Day Strategy Recap Our Data Center Business Model Strategy Recap 2 Strategy Recap & CMD Targets 2024 CMD Recap RECAP CMD 2024 | WE HAVE MADE GREAT PROGRESS IN THE 5 STRATEGIC PRIORITIES IDENTIFIED IN THE 2024 CMD, DELIVERING TANGIBLE RESULTS Top-line growth Margin expansion Operational Expand our margins by delivering high-value services, with reinforced engineering capabilities, supply chain and systems The Group has increased its backlog, mainly driven by high growth segments Ba ...

Nasdaq: ICG 1 Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding Intchains Group Limited's ("Intchains" or the "Company") future results of operations and financial position, financial targets, business strategy, plans and objectives for future operations, are forward-looking statements. The Company has based these forward-looking statements largely on its current estimates ...

Financial Performance & Growth - CLINUVEL achieved its 9th consecutive annual profit in FY2025[12] - Total revenues, interest, and other income reached A$105.3 million (US$70 million), a 10% increase[13] - Cash reserves increased by 22% to A$224.1 million (US$148 million)[13] - The company reinvests approximately 40% of its profits into RD&I[15] - Net profit margin is 34%[15] Product Pipeline & Market - SCENESSE® is commercially available for adult EPP in multiple regions[8] - CLINUVEL is expanding SCENESSE® to treat adolescent EPP and vitiligo[8] - The total addressable market (TAM) for vitiligo is estimated at US$4.5 billion[10] - The company is pursuing M&A opportunities targeting pharmaceutical and PhotoCosmetic products[11] U.S. Expansion - American revenues now account for over 50% of total revenue[3] - The company is planning a Nasdaq uplisting of its ADRs (Level 2) with an SEC filing expected in Q4[3]